Keyphrases
4-cycle
47%
Advanced Breast Cancer
47%
Advanced Gastroesophageal Cancer
47%
Albumin Paclitaxel
47%
Alternative Schedule
47%
Aromatase Inhibitor Therapy
52%
Aromatase Inhibitor-induced Arthralgia
47%
Blood Tumor mutational Burden
47%
Carboplatin
94%
Cetuximab
47%
Circulating Tumor DNA (ctDNA)
57%
Clinical Trials
47%
Colorectal Cancer
47%
Cyclin-dependent Kinase 4 (CDK4)
47%
Docetaxel
47%
ErbB2
47%
First-line Therapy
53%
FOLFIRINOX
47%
FOLFOX Chemotherapy
47%
Gastrointestinal Cancer
53%
Genome Complexity
47%
Head-and-neck Cancer
47%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
47%
HER2-negative Metastatic Breast Cancer
47%
High Dose
47%
Letrozole
62%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
47%
Median Progression-free Survival
40%
Mutation Profiling
47%
Nab-paclitaxel
37%
Non-randomized Clinical Trial
47%
Objective Response Rate
58%
Older Patients
47%
Palbociclib
52%
Pathological Complete Response
47%
Pathological Response
47%
Pemetrexed
47%
Phase I Trial
47%
Phase II Trial
100%
Preoperative Treatment
47%
Radiation Therapy
47%
Randomized Controlled Trial
47%
Recurrent or Metastatic
47%
Resistance to Endocrine Therapy
47%
Serum Thymidine Kinase 1
47%
Temsirolimus
47%
Triple-negative Breast Cancer
47%
Vitamin D3
47%
Young Patients
47%
YpT0
47%
Pharmacology, Toxicology and Pharmaceutical Science
Adenocarcinoma
47%
Adverse Event
15%
Anastrozole
11%
Aromatase Inhibitor
94%
Arthralgia
47%
Breast Cancer
22%
Carboplatin
94%
Cetuximab
47%
Cholecalciferol
47%
Clinical Trial
94%
Colon Carcinoma
11%
Diarrhea
11%
Digestive System Cancer
11%
Diseases
50%
Docetaxel
47%
Endocrine Therapy
53%
Fluorouracil
30%
Folinic Acid
23%
Fulvestrant
14%
Head and Neck Cancer
47%
Head and Neck Squamous Cell Carcinoma
33%
Hormone Receptor
23%
Human Papillomavirus
13%
Irinotecan
23%
Letrozole
44%
Malignant Neoplasm
18%
Mammalian Target of Rapamycin
18%
Metastatic Breast Cancer
66%
Monotherapy
11%
Nausea
11%
Neoplasm
82%
Neutropenia
40%
Non Small Cell Lung Cancer
47%
Overall Survival
55%
Oxaliplatin
23%
Paclitaxel
47%
Palbociclib
52%
Pemetrexed
47%
Phase II Trials
52%
Progression Free Survival
89%
Randomized Controlled Trial
47%
Sensory Neuropathy
11%
Solid Malignant Neoplasm
11%
Tamoxifen
47%
Temsirolimus
47%
Thymidine Kinase 1
47%
Toxicity
23%
Trastuzumab
35%
Triple Negative Breast Cancer
47%
Vitamin D
37%
Medicine and Dentistry
Adverse Event
15%
Anastrozole
11%
Arm
56%
Aromatase Inhibitor
47%
Breast Cancer
65%
Cancer Treatment
9%
Carboplatin
94%
CD8 Antigen
9%
Cetuximab
47%
Circulating Tumor DNA
57%
Clinical Trial
47%
Cytotoxicity
9%
Diseases
21%
DNA Determination
12%
Docetaxel
47%
Exome Sequencing
29%
Fluorouracil
22%
FOLFOX
47%
Fulvestrant
14%
Gamma Interferon
9%
Gastrointestinal Cancer
47%
Head and Neck Cancer
47%
Head and Neck Squamous Cell Carcinoma
33%
Health Care Cost
11%
Hormone Receptor
18%
Hormone Therapy
56%
Immunity
37%
Lenabasum
23%
Letrozole
44%
Malignant Neoplasm
25%
Metastatic Breast Cancer
66%
Molecular Profiling
13%
Monotherapy
11%
Neoadjuvant Chemotherapy
9%
Neoplasm
73%
Neutropenia
18%
Overall Survival
20%
Paclitaxel
47%
Palbociclib
52%
Phase II Trials
52%
Preoperative Radiotherapy
15%
Preoperative Treatment
47%
Progression Free Survival
41%
Radiation Therapy
47%
Rectum Cancer
47%
Recurrent Disease
9%
Tamoxifen
47%
Thymidine Kinase 1
47%
Triple Negative Breast Cancer
47%
Wart Virus
13%